Savant Capital’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.19M | Buy |
6,479
+2,911
| +82% | +$536K | 0.01% | 565 |
|
|
2025
Q4 | $628K | Buy |
3,568
+154
| +5% | +$25.2K | ﹤0.01% | 745 |
|
|
2025
Q3 | $478K | Buy |
3,414
+405
| +13% | +$54.7K | ﹤0.01% | 812 |
|
|
2025
Q2 | $378K | Sell |
3,009
-250
| -8% | -$31.1K | ﹤0.01% | 856 |
|
|
2025
Q1 | $446K | Sell |
3,259
-920
| -22% | -$132K | ﹤0.01% | 706 |
|
|
2024
Q4 | $639K | Buy |
4,179
+423
| +11% | +$71.3K | 0.01% | 801 |
|
|
2024
Q3 | $728K | Buy |
3,756
+1,342
| +56% | +$281K | 0.01% | 744 |
|
|
2024
Q2 | $560K | Sell |
2,414
-121
| -5% | -$26.3K | 0.01% | 751 |
|
|
2024
Q1 | $547K | Buy |
2,535
+166
| +7% | +$38.9K | 0.01% | 703 |
|
|
2023
Q4 | $613K | Buy |
2,369
+156
| +7% | +$38.3K | 0.01% | 517 |
|
|
2023
Q3 | $569K | Buy |
2,213
+616
| +39% | +$165K | 0.01% | 494 |
|
|
2023
Q2 | $455K | Buy |
1,597
+414
| +35% | +$123K | 0.01% | 532 |
|
|
2023
Q1 | $329K | Buy |
1,183
+152
| +15% | +$42.1K | 0.01% | 574 |
|
|
2022
Q4 | $265K | Buy |
1,031
+158
| +18% | +$44.6K | 0.01% | 497 |
|
|
2022
Q3 | $233K | Buy |
+873
| New | +$185K | 0.01% | 478 |
|
|
2022
Q2 | – | Sell |
-1,143
| Closed | -$241K | – | 561 |
|
|
2022
Q1 | $241K | Buy |
1,143
+30
| +3% | +$6.52K | 0.01% | 507 |
|
|
2021
Q4 | $267K | Sell |
1,113
-128
| -10% | -$32.9K | 0.01% | 470 |
|
|
2021
Q3 | $351K | Buy |
1,241
+84
| +7% | +$27.5K | 0.01% | 386 |
|
|
2021
Q2 | $401K | Sell |
1,157
-14
| -1% | -$4.24K | 0.02% | 349 |
|
|
2021
Q1 | $328K | Buy |
1,171
+53
| +5% | +$14.3K | 0.02% | 353 |
|
|
2020
Q4 | $274K | Sell |
1,118
-99
| -8% | -$25.5K | 0.02% | 368 |
|
|
2020
Q3 | $345K | Buy |
1,217
+143
| +13% | +$39.9K | 0.02% | 309 |
|
|
2020
Q2 | $287K | Buy |
1,074
+54
| +5% | +$16.2K | 0.02% | 330 |
|
|
2020
Q1 | $323K | Buy |
1,020
+173
| +20% | +$52.5K | 0.03% | 280 |
|
|
2019
Q4 | $251K | Buy |
+847
| New | +$235K | 0.03% | 309 |
|
|
2019
Q2 | – | Sell |
-874
| Closed | -$207K | – | 333 |
|
|
2019
Q1 | $207K | Hold |
874
| – | – | 0.04% | 268 |
|
|
2018
Q4 | $263K | Sell |
874
-48
| -5% | -$15.3K | 0.06% | 223 |
|
|
2018
Q3 | $326K | Sell |
922
-48
| -5% | -$16.5K | 0.06% | 217 |
|
|
2018
Q2 | $282K | Buy |
970
+58
| +6% | +$16.3K | 0.06% | 224 |
|
|
2018
Q1 | $250K | Buy |
912
+72
| +9% | +$22.4K | 0.05% | 241 |
|
|
2017
Q4 | $268K | Sell |
840
-32
| -4% | -$10.3K | 0.06% | 237 |
|
|
2017
Q3 | $273K | Buy |
872
+36
| +4% | +$10.7K | 0.06% | 219 |
|
|
2017
Q2 | $227K | Sell |
836
-10
| -1% | -$2.64K | 0.05% | 247 |
|
|
2017
Q1 | $231K | Buy |
846
+30
| +4% | +$8.48K | 0.06% | 231 |
|
|
2016
Q4 | $231K | Sell |
816
-20
| -2% | -$5.93K | 0.06% | 230 |
|
|
2016
Q3 | $262K | Buy |
+836
| New | +$248K | 0.07% | 204 |
|
|
2016
Q2 | – | Sell |
-830
| Closed | -$216K | – | 253 |
|
|
2016
Q1 | $216K | Sell |
830
-476
| -36% | -$126K | 0.07% | 210 |
|
|
2015
Q4 | $400K | Buy |
1,306
+426
| +48% | +$122K | 0.12% | 129 |
|
|
2015
Q3 | $257K | Buy |
880
+4
| +0.5% | +$1.32K | 0.09% | 176 |
|
|
2015
Q2 | $354K | Hold |
876
| – | – | 0.12% | 144 |
|
|
2015
Q1 | $370K | Buy |
876
+10
| +1% | +$3.94K | 0.13% | 135 |
|
|
2014
Q4 | $294K | Buy |
866
+30
| +4% | +$9.71K | 0.11% | 159 |
|
|
2014
Q3 | $277K | Hold |
836
| – | – | 0.12% | 147 |
|
|
2014
Q2 | $264K | Hold |
836
| – | – | 0.11% | 148 |
|
|
2014
Q1 | $256K | Hold |
836
| – | – | 0.12% | 146 |
|
|
2013
Q4 | $234K | Buy |
+836
| New | +$216K | 0.11% | 145 |
|
Other funds holding BIIB
VCM
VPM
Savant Capital's BIIB Position: Q1 2026 in Review
Savant Capital increased its Biogen (BIIB) stake by 82% in Q1 2026, buying an estimated $536K and bringing the position to 6,479 shares worth $1.19M. The position accounts for 0.01% of the portfolio, ranked #565.
Savant Capital first reported a position in BIIB in Q4 2013 and has held it in 46 quarters since. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Savant Capital held 6,479 shares of Biogen worth $1.19M as of Q1 2026.
- Savant Capital bought 2,911 Biogen shares in Q1 2026, an estimated $536K.
- Biogen made up 0.01% of Savant Capital's portfolio in Q1 2026, its #565 holding.
- Savant Capital first reported a position in Biogen in Q4 2013 and has held it in 46 quarters since.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Savant Capital's 13F filing for Q1 2026, filed 4 May 2026.